ReviewInternational immunology2014
Controlling immune responses by targeting antigens to dendritic cell subsets and B cells.
Review in International immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Exercise after influenza or COVID-19 vaccination increases serum antibody without an increase in side effects.Brain, behavior, and immunity · 2022Article
- Immunogenicity of theVaccines · 2022Article
- Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.Oncoimmunology · 2022Article
- Tolerogenic vaccines: Targeting the antigenic and cytokine niches of FOXP3Cellular immunology · 2020Review
- Article
- Targeting Dendritic Cells with Antigen-Delivering Antibodies for Amelioration of Autoimmunity in Animal Models of Multiple Sclerosis and Other Autoimmune Diseases.Antibodies (Basel, Switzerland) · 2020Review
- The CTA1-DD adjuvant strongly potentiates follicular dendritic cell function and germinal center formation, which results in improved neonatal immunization.Mucosal immunology · 2020Article
- Targeting Antigens to CD180 but Not CD40 Programs Immature and Mature B Cell Subsets to Become Efficient APCs.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Advancing immunomodulation by in vivo antigen delivery to DEC-205 and other cell surface molecules using recombinant chimeric antibodies.International immunopharmacology · 2019Review
- Article
- DC Subsets Regulate Humoral Immune Responses by Supporting the Differentiation of Distinct Tfh Cells.Frontiers in immunology · 2019Article
- Endocytosis Deficient Murine Xcl1-Fusion Vaccine Enhances Protective Antibody Responses in Mice.Frontiers in immunology · 2019Article
- Article
- Protection of mice deficient in mature B cells from West Nile virus infection by passive and active immunization.PLoS pathogens · 2017Article
- CD301beLife · 2016Article
- Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody.Clinical and experimental immunology · 2016Article
- Antigen targeting reveals splenic CD169+ macrophages as promoters of germinal center B-cell responses.European journal of immunology · 2015Article
- Optimization of multi-epitopic HIV-1 recombinant protein expression in prokaryote system and conjugation to mouse DEC-205 monoclonal antibody: implication for in-vivo targeted delivery of dendritic cells.Iranian journal of basic medical sciences · 2015Article
- Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.Journal of immunology research · 2015Review
- Targeting antigens through blood dendritic cell antigen 2 on plasmacytoid dendritic cells promotes immunologic tolerance.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Delivering antigens in vivo by coupling them to mAbs specific for unique receptors on antigen-presenting cells (APCs) is a promising approach for modulating immune responses. Antigen delivery to receptors found on myeloid dendritic cell (DC) subsets, plasmacytoid DCs and B cells has shown them all to be viable targets to stimulate either the cellular or humoral arms of the immune system. It is now evident that antigen-targeting approaches can also be used to invoke antigen-specific inhibition of immune responses. The outcome of activation versus inhibition is determined by a combination of factors that include the choice of APC, the receptor that is targeted, whether to include an adjuvant and, if so, which adjuvant to employ. In addition to their use as a means to modulate immune responses, antigen-targeting systems are also a useful method to investigate the function of DC subsets and the early mechanistic events that underlie the initiation of both cellular and humoral immune responses. In this review, we focus on the literature surrounding the control of B-cell responses when antigen is delivered to various APC subsets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.